Liver Metastases Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment Type, By Primary Cancer (Colorectal Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032
- Published Date:Feb-2024
- Pages: 118
- Format: PDF
- Report ID: PM4359
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
The global liver metastases treatment market was valued at USD 1.78 billion in 2023 and is expected to grow at a CAGR of 6.9% during the forecast period.
Liver metastases, a common occurrence in breast and colorectal cancers, affect individuals across various age groups, including both young women and men. The rising number of cases indicates a growing burden on healthcare systems, which is anticipated to drive the demand for treatment in the foreseeable future. American Cancer Society projects an estimated 1,958,310 new cancer cases and 609,820 deaths in the United States in 2023. This data highlights the significant impact of cancer, emphasizing the need for ongoing efforts in research, prevention, and treatment to address the challenges posed by liver metastases and other cancer-related conditions.
Continuing clinical trials and favorable outcomes have the potential to enrich the global market with a more varied and effective array of treatment modalities, addressing the demand for enhanced solutions. Additionally, regulatory support plays a pivotal role in endorsing the safety and efficacy of novel therapies, further contributing to the expansion of the market.
- For instance, in February 2023, AstraZeneca secured EU approval for Imfinzi & Imjudo immunotherapy combinations, underscoring the positive results derived from the HIMALAYA & POSEIDON Phase III trials. The collaborative endeavors in drug development, coupled with regulatory backing, contribute synergistically to innovation and expansion of the market.
The Centers for Medicare & Medicaid Services (CMS) have recently approved an Innovation Center concept aimed at elevating the standard of care for cancer patients undergoing radiotherapy. The newly approved Radiation Oncology (RO) Model emphasizes value-based care through the establishment of more straightforward and predictable payment structures. These structures incentivize both clinically and financially sound treatments, aiming to enhance the standards of quality and outcomes in cancer treatment. RO Model is projected to generate savings of USD 230 million for Medicare over five years.
To Understand More About this Research: Request a Free Sample Report
The market is being propelled by the encouraging outcomes from expanding research initiatives. Numerous government and non-profit organizations are actively engaged in research endeavors. For instance, the National Cancer Institute is currently conducting the P01 program, which aims to comprehend the shared mechanisms underlying the development of liver metastases across diverse tumor models. The successful conclusion of this study is anticipated to stimulate the advancement of innovative diagnostics and medications for the treatment of liver metastases in the years to come.
Growth Drivers
Advancements in targeted therapies and immunotherapy options.
The liver metastases treatment market is experiencing significant market growth due to notable advancements in targeted therapies and immunotherapy options. These cutting-edge treatments have revolutionized the approach to liver metastases, offering more effective and personalized solutions. The development of precision medicine and molecular targeting has led to enhanced therapeutic outcomes, providing patients with tailored and efficient interventions. The expanding array of immunotherapeutic strategies, including immune checkpoint inhibitors, has shown promising results in bolstering the immune system's ability to combat metastatic liver lesions. This paradigm shift in treatment approaches reflects a positive trajectory for the Liver Metastases Treatment Market, contributing to improved patient outcomes and a brighter outlook for individuals facing this challenging medical condition.
Report Segmentation
The market is primarily segmented based on treatment type, primary cancer, distribution channel, and Region.
|
By Treatment Type |
By Primary Cancer |
By Distribution Channel |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Treatment Type Analysis
The targeted therapy segment held a significant market share in 2023
The targeted therapy segment dominated the global market share. This dominance is attributed to the widespread availability of molecularly targeted therapy drugs, positioning them as a highly effective alternative medicine compared to other treatment approaches. Notably, Cetuximab serves as a primary drug therapy for patients with colon cancer liver metastases (CCLM). Consequently, the increasing utilization of targeted therapy medications for the treatment of colorectal cancer liver metastases (CRLM) is anticipated to be a significant driver for market growth.
The chemotherapy segment is estimated to grow at the highest CAGR over the forecasted period. This growth is linked to the high historical usage of chemotherapy, driven by the escalating incidence of primary cancers leading to liver metastases in patients. Systemic chemotherapy is predominantly employed in individuals with unresectable hepatocellular carcinoma, primarily due to its ability to prolong survival compared to alternative treatment approaches. Various research studies have indicated that combining oxaliplatin with fluorouracil and calcium folinate enhances the survival rate in patients with CRLM.
By Primary Cancer Analysis
Colorectal cancer segment accounted for the largest market share in 2023
The colorectal cancer segment accounted for the largest market share in 2023. This dominance is a result of the increasing incidence of colorectal liver metastases, with the liver being the primary site for distant metastasis in the male population with colorectal cancer. American Cancer Society reports that colorectal cancer, excluding skin cancers, stands as the third most prevalent cancer in the United States, with an estimated 106,970 new colon and 46,050 rectal cases in 2023. Various research articles and studies indicate that around 25-30% of patients diagnosed with colorectal cancer eventually develop liver metastases. Hence, emphasizing early diagnosis and treatment of colorectal cancer becomes crucial to mitigate the burden of liver metastases.
The breast cancer segment will grow rapidly. It is primarily driven by the increased risk of liver metastases in women with metastatic breast cancer. As per Breastcancer.org, approximately 50% of individuals diagnosed with breast cancer experience liver metastases, signifying a notable occurrence.
Regional Insights
North America dominated the global market in 2023
North America dominated the global market share. This supremacy is due to the region's access to advanced treatment options, facilitating improved treatment accessibility, and favorable reimbursement policies, especially for stage 4 cancers. Annually, there are approximately 140,000 individuals diagnosed with liver metastases in the United States. Furthermore, in August 2023, Delcath Systems received FDA approval for the Hepzato Kit in the treatment of unresectable hepatic-dominant metastatic uveal melanoma. This approval is expected to propel market growth in the region.
Asia Pacific will grow rapidly. The growth trajectory is further supported by increasing healthcare expenditure and favorable insurance policies and coverage. The market is poised to benefit from a significant growth opportunity due to the lack of effective screening practices and limited access to healthcare in the region, leading to the diagnosis of cancers predominantly at advanced stages.
Key Market Players & Competitive Insights
The industry is characterized by intense strategic competition, with market players engaging in activities like strategic collaborations, launching new products, acquisitions, technological advancements, and expanding their presence in different regions.
Some of the major players operating in the global market include:
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Cadila Pharmaceuticals
- Eli Lilly and Company
- Ono Pharmaceutical
- Pfizer, Inc.
- Roche Ltd.
Recent Developments
- In April 2023, Ablaze Pharmaceuticals revealed plans to commence clinical trials for an innovative peptide drug targeting GPC3 to address liver cancer in China. This milestone follows the company's licensing agreement for the ground-breaking drug candidate, which was established through a pre-existing collaboration with RayzeBio.
- In March 2023, Researchers at Newcastle secured £6 million (approximately USD 7.32 million) in funding from Cancer Research UK for various cancer studies. The grants encompass funding for studies on medulloblastoma, bowel cancer, melanoma treatment, & cancer screening programs.
- In March 2023, The USC Norris Comprehensive Cancer Center partnered with Auransa for a phase 1 clinical trial evaluating AU409, an innovative drug designed to target liver cancer and solid tumors.
Liver Metastases Treatment Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 1.89 billion |
|
Revenue Forecast in 2032 |
USD 3.23 billion |
|
CAGR |
6.9% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments Covered |
By Treatment Type, By Primary Cancer, By Distribution Channel, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key Companies |
AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Eli Lilly and Company, Ono Pharmaceutical, Pfizer, Inc., Roche Ltd. |
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The liver metastases treatment market size is expected to reach USD 3.23 billion by 2032
Key players in the market are Eli Lilly, Bayer, Ono Pharmaceutical, Pfizer, Bristol-Myers
North America contribute notably towards the global Liver Metastases Treatment Market
The global liver metastases treatment market is expected to grow at a CAGR of 6.9% during the forecast period.
The Liver Metastases Treatment Market report covering key segments are treatment type, primary cancer, distribution channel, and Region.
© 2024 Polaris Market Research and Consulting. All rights reserved
